Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: teriflunomide (HMR1726)

First Posted Date: 2005-09-28

Last Posted Date: 2015-03-25

Lead Sponsor: Sanofi

Target Recruit Count: 147

Registration Number: NCT00228163

Locations: 🇨🇦
Investigational Site Number 12, Montreal, Canada
🇨🇦
Investigational Site Number 11, Montreal, Canada
🇨🇦
Investigational Site Number 17, Vancouver, Canada

and more 13 locations

Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease

Phase 2

Completed

Conditions: Parkinson Disease

First Posted Date: 2005-09-28

Last Posted Date: 2008-12-23

Lead Sponsor: Sanofi

Target Recruit Count: 564

Registration Number: NCT00228150

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guilford Surrey, United Kingdom

Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant

Phase 3

Terminated

Conditions: Carotid Artery Plaque
Arteriosclerosis
Obesity
Metabolic Syndrome X

Interventions: Drug: Placebo (for Rimonabant)
Drug: Rimonabant

First Posted Date: 2005-09-28

Last Posted Date: 2016-05-20

Lead Sponsor: Sanofi

Target Recruit Count: 661

Registration Number: NCT00228176

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom

Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers

Phase 1

Completed

Conditions: Clostridium Infections

Interventions: Biological: Vaccine diluent buffer (Placebo)
Biological: C. difficile toxoid vaccine (2 µg)
Biological: C. difficile toxoid vaccine (10 µg)
Biological: C. difficile toxoid vaccine (50 µg)

First Posted Date: 2005-09-22

Last Posted Date: 2012-04-11

Lead Sponsor: Sanofi

Target Recruit Count: 48

Registration Number: NCT00214461

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
University of Kentucky, Lexington, Kentucky, United States

Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease

Phase 2

Completed

Conditions: Parkinson Disease

First Posted Date: 2005-09-22

Last Posted Date: 2008-12-23

Lead Sponsor: Sanofi

Target Recruit Count: 183

Registration Number: NCT00220272

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom

Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

Phase 4

Terminated

Conditions: Anemia

Interventions: Drug: sodium ferric gluconate
Drug: Oral Iron

First Posted Date: 2005-09-22

Last Posted Date: 2021-06-24

Lead Sponsor: Sanofi

Target Recruit Count: 112

Registration Number: NCT00223938

Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer

Phase 2

Completed

Conditions: Prostatic Neoplasm

First Posted Date: 2005-09-15

Last Posted Date: 2008-12-23

Lead Sponsor: Sanofi

Target Recruit Count: 232

Registration Number: NCT00174863

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guilford Surrey, United Kingdom
🇦🇺
sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia

Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2005-09-15

Last Posted Date: 2011-01-11

Lead Sponsor: Sanofi

Target Recruit Count: 390

Registration Number: NCT00174681

Locations: 🇸🇮
Sanofi-Aventis, Ljubljana, Slovenia

Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Lung Neoplasms

Interventions: Drug: docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy
Drug: docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin

First Posted Date: 2005-09-15

Last Posted Date: 2010-02-17

Lead Sponsor: Sanofi

Target Recruit Count: 72

Registration Number: NCT00174772

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guilford, United Kingdom

CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease

Phase 3

Completed

Conditions: Arterial Occlusive Diseases

First Posted Date: 2005-09-15

Last Posted Date: 2011-01-11

Lead Sponsor: Sanofi

Target Recruit Count: 1460

Registration Number: NCT00174759

Locations: 🇬🇧
Sanofi-Aventis, Guildford, United Kingdom

Home Terms & Conditions Privacy Policy